S. Stein

554 total citations
15 papers, 448 citations indexed

About

S. Stein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, S. Stein has authored 15 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in S. Stein's work include HER2/EGFR in Cancer Research (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). S. Stein is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). S. Stein collaborates with scholars based in United States, United Kingdom and Israel. S. Stein's co-authors include Harold J. Burstein, Kimberly Blackwell, S. D. Rubin, Sandra Franco, Vanessa Salazar, Anna Maria Storniolo, Mayur M. Amonkar, Beth Sherrill, Ceri Hirst and Yun Wu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

S. Stein

15 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Stein United States 10 306 113 102 77 73 15 448
Joanna Pikiel Poland 13 362 1.2× 129 1.1× 160 1.6× 113 1.5× 95 1.3× 43 532
Pam K. Mangat United States 12 468 1.5× 35 0.3× 273 2.7× 140 1.8× 322 4.4× 47 644
Cristina Sonetto Italy 12 475 1.6× 43 0.4× 160 1.6× 228 3.0× 213 2.9× 22 781
Valerie Bée United States 9 297 1.0× 140 1.2× 71 0.7× 145 1.9× 145 2.0× 13 475
David Mallery United States 4 247 0.8× 31 0.3× 212 2.1× 130 1.7× 329 4.5× 5 498
Ratislav Bahleda France 12 218 0.7× 40 0.4× 128 1.3× 168 2.2× 114 1.6× 31 458
JoAnne Zujewski United States 12 224 0.7× 120 1.1× 123 1.2× 87 1.1× 208 2.8× 20 440
Hagen Kennecke Canada 9 248 0.8× 48 0.4× 70 0.7× 75 1.0× 127 1.7× 14 398
James E. Krook United States 7 297 1.0× 48 0.4× 138 1.4× 70 0.9× 110 1.5× 9 427
Nancy G. Iskander United States 3 218 0.7× 18 0.2× 199 2.0× 116 1.5× 295 4.0× 5 429

Countries citing papers authored by S. Stein

Since Specialization
Citations

This map shows the geographic impact of S. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Stein more than expected).

Fields of papers citing papers by S. Stein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Stein. The network helps show where S. Stein may publish in the future.

Co-authorship network of co-authors of S. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of S. Stein. A scholar is included among the top collaborators of S. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Stein. S. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Slosberg, Eric D., Susan Snodgrass, Claudia Lebedinsky, et al.. (2015). The Signature Program: Bringing the Protocol to the Patient. Clinical Pharmacology & Therapeutics. 98(2). 124–126. 23 indexed citations
3.
Spraggs, Colin F., Linda P. Briley, Nan Bing, et al.. (2009). Hyperbilirubinemia in Lapatinib Treated Patients Is Associated with Gilbert's Syndrome UGT1A1 Polymorphism.. Cancer Research. 69(24_Supplement). 1112–1112. 5 indexed citations
4.
Blackwell, Kimberly, Harold J. Burstein, George W. Sledge, et al.. (2009). Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.. Cancer Research. 69(24_Supplement). 61–61. 38 indexed citations
5.
Johnston, Stephen, Charles Swanton, Vanessa Salazar, et al.. (2009). Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy.. Cancer Research. 69(24_Supplement). 706–706. 1 indexed citations
6.
Esteva, Francisco J., Sandra Franco, Robert A. Somer, et al.. (2009). An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+ Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 5085–5085. 1 indexed citations
7.
Sherrill, Beth, et al.. (2008). Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British Journal of Cancer. 99(5). 711–715. 33 indexed citations
8.
Sherrill, Beth, Mayur M. Amonkar, Yun Wu, et al.. (2008). Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. British Journal of Cancer. 99(10). 1572–1578. 62 indexed citations
9.
Burstein, Harold J., Anna Maria Storniolo, Sandra Franco, et al.. (2008). A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Annals of Oncology. 19(6). 1068–1074. 171 indexed citations
10.
Gómez, Henry, Miguel A. Chavez, Dinesh Chandra Doval, et al.. (2007). Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer. Journal of Clinical Oncology. 25(18_suppl). 10562–10562. 10 indexed citations
11.
Geyer, Charles E., Anne Marie Martin, B. Newstat, et al.. (2007). Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. Journal of Clinical Oncology. 25(18_suppl). 1035–1035. 26 indexed citations
12.
Sherrill, Beth, Amanda A. Allshouse, Mayur M. Amonkar, & S. Stein. (2007). A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1026–1026. 3 indexed citations
13.
Stein, S., Carla Grosmann, E. Schmitt, et al.. (2005). COMBO-FISH for focussed fluorescence labelling of gene domains: 3D-analysis of the genome architecture of abl and bcr in human blood cells. Cell Biology International. 29(12). 1038–1046. 16 indexed citations
14.
Stein, S., et al.. (1998). Blood loss in major lipoplasty procedures with the tumescent technique*. Aesthetic Surgery Journal. 18(1). 30–35. 11 indexed citations
15.
Roman, Lynda D., et al.. (1997). Pelvic examination, tumor marker level, and gray-scale and doppler sonography in the prediction of pelvic cancer. Obstetrics and Gynecology. 89(4). 493–500. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanna Pikiel Breakdown of academic impact, for papers by Pam K. Mangat Breakdown of academic impact, for papers by Cristina Sonetto Breakdown of academic impact, for papers by Valerie Bée Breakdown of academic impact, for papers by David Mallery Breakdown of academic impact, for papers by Ratislav Bahleda Breakdown of academic impact, for papers by JoAnne Zujewski Breakdown of academic impact, for papers by Hagen Kennecke Breakdown of academic impact, for papers by James E. Krook Breakdown of academic impact, for papers by Nancy G. Iskander
Rankless by CCL
2026